Unfortunately, the single-agent efficacy of navitoclax against SCLC in phase-II clinical trials was limited [13] because of the intratumoral heterogeneity and dependence of some of the cells within a tumor on other BCL-2 family proteins such as MCL-1. This evidence concerns the gene BCL2 and small cell lung carcinoma.